Argentina: No Patents For Drugs Till 2005

7 November 1994

The proposed patent protection legislation sent by a Senate committee in the Argentine Congress for debate in the full Senate last month would provide patent protection for products 180 days after the law is implemented, except for pharmaceuticals, which would not receive patent cover until January 1, 2005.

A bill submitted by President Carlos Menem, which has been with the Senate since the early part of the year, would provide 20-year patent protection for pharmaceuticals as soon as it is passed, but local observers believe that continued opposition in the House of Deputies means that there is now very little chance of this bill passing before this Congress ends on November 30.

Lobbying by the local drug manufacturers, who control around 60% of the $3.4 billion domestic market, has stalled President Menem's bill for more than three years despite pressure from the US Trade Representative on behalf of the multinationals (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight